Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 4/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | ALB | P02768 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28465690 | 0.88 | CCKBR (0.71) | CCKBRMEN1LMNAALBKMT2A | |
| SCHEMBL30767671 | 0.88 | CCKBR (0.71) | CCKBRMEN1LMNAALBKMT2A | |
| SCHEMBL21272207 | 0.88 | CCKBR (0.77) | CCKBRMEN1LMNAALBKMT2A | |
| SCHEMBL21272212 | 0.88 | CCKBR (0.77) | CCKBRMEN1LMNAALBKMT2A | |
| SCHEMBL11772245 | 0.88 | CCKBR (0.73) | CCKBRMEN1LMNAALBKMT2A | |
| SCHEMBL9527025 | 0.87 | CCKBR (0.74) | CCKBRMEN1LMNAALBKMT2A | |
| SCHEMBL9527020 | 0.87 | CCKBR (0.74) | CCKBRMEN1LMNAALBKMT2A | |
| SCHEMBL20473274 | 0.86 | CCKBR (0.68) | CCKBRMEN1LMNAALBKMT2A | |
| SCHEMBL21272180 | 0.86 | CHRM1 (0.77) | CCKBRMEN1LMNAALBKMT2A | |
| SCHEMBL21272182 | 0.86 | CHRM1 (0.77) | CCKBRMEN1LMNAALBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071432-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071432-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | PMP22, INA, SMN1; SMN2 | CCKBR 1964/4885MEN1 909/4885LMNA 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.